RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple therapy targets aggressive blood cancer in early trial
Disease control Recruiting nowThis study tests a combination of three treatments for Richter's transformation, an aggressive form of blood cancer. The approach uses the patient's own immune cells (liso-cel) plus two drugs (nivolumab and ibrutinib) to boost the immune system and block cancer growth. About 20 a…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New drug combo targets aggressive blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests the safety and effectiveness of combining two drugs—zanubrutinib and odronextamab—in 23 adults with Richter's transformation, a fast-growing lymphoma that arises from chronic lymphocytic leukemia. Zanubrutinib blocks a protein that helps cancer grow, …
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can safely and effectively treat adults with diffuse large B-cell lymphoma that has come back or stopped responding to prior therapy. The drugs work by attaching to cancer cells and e…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 03:24 UTC
-
New CAR T-Cell attack on tough blood cancers shows early promise
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to prior treatments. The therapy…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New combo therapy targets tough lymphoma
Disease control Recruiting nowThis study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that has returned or not responded to prior treatment. About 24 participants will receive…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated May 18, 2026 12:00 UTC